Ocean Biomedical, Inc. OCEA

Annual Quarterly

No annual revenue total was found in OCEAN BIOMEDICAL, INC.'s SEC filings.

Ocean Biomedical, Inc. (OCEA) files with the SEC under industry code 2834, Pharmaceutical Preparations.

Revenue
—
Net income (TTM)
$-30.72M
-4.6% vs year-ago TTM
Operating cash flow (TTM)
$-4.05M
+44.2% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.71
+34.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
166.01M
+376.8% vs prior year
Net cash
$-2.20M
FY 2023
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
OCEA (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
, Emerging growth company
SEC CIK
1869974
Former names
Ocean Biomedical, Inc./DE (until Feb 15, 2023); Aesther Healthcare Acquisition Corp. (until Feb 14, 2023)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
Operating income
-$3.8M
-$10.2M
-$16.1M
Net income
-$9.5M
-$114.5M
-$17.4M
Diluted EPS
-$0.34
-$4.35
—
Operating cash flow
-$4.2M
-$9.4M
-$993,000
Total assets
$902,000
$5.5M
$1.8M
Total liabilities
$98.5M
$96.3M
$12.7M
Stockholders' equity
-$97.6M
-$90.8M
-$10.8M
Cash and investments
$200,000
$1.0M
—
Total debt
—
$3.2M
—

Recent SEC filings

Form Description Filed Period
8-K Current report
Listing notice, Officer or director change, Other events
 Aug 5, 2025 Jul 31, 2025
8-K Current report
Listing notice
 Jul 23, 2025 Jul 17, 2025
8-K Current report
Agreement ended
 Jul 16, 2025 Jul 10, 2025
8-K Current report
Agreement ended
 Jun 13, 2025 Jun 12, 2025
10-Q Quarterly report May 15, 2025 Mar 31, 2025
10-K/A Amended annual report Apr 29, 2025 Dec 31, 2024

All 255 Ocean Biomedical, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.